Head-to-head evidence
bb21217 vs Belantamab mafodotin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
bb21217
Developed by 2seventy bio, Inc. (wholly-owned subsidiary of Bristol Myers Squibb)
NCT03274219 · Phase 1 · completed
There was no control group and no blinding: everyone in the study received bb21217, and the trial was designed to check safety rather than measure effectiveness. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Belantamab mafodotin
Marketed by GlaxoSmithKline
NCT03525678 · Phase 2 · completed
This was a randomized but open-label phase 2 study in which all participants received belantamab mafodotin at one of two doses or formulations; there was no placebo or active comparator arm and no blinding. The primary endpoint was overall response rate by independent review, a clinical response measure, but the results are reported as per-arm rates with confidence intervals and no formal statistical comparison against a control, so the study cannot distinguish drug effect from natural history or placebo effect. The evidence is therefore descriptive phase 2 evidence of activity, not strong comparative evidence.
Next expected readout: October 2026 · NCT05573802 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bb21217's landscape · Belantamab mafodotin's landscape